Description
Methasterone (Superdrol, M-Drol) is a synthetic dihydrotestosterone derivative with 17α-methyl group and additional 2α-methyl modification. The substance was originally synthesized and published in 1956 but never clinically developed. In the early 2000s Methasterone appeared as a prohormone supplement in the US market and was banned after several hepatotoxicity case reports.
Per study reports Methasterone binds with high affinity to the androgen receptor and is resistant to aromatization. Anabolic action is very potent - reports from the recreational community speak of 1-3kg lean mass gain per week in the first 2-3 weeks, similar to or stronger than Anadrol or Dianabol but without water retention.
The central danger is hepatotoxicity: Methasterone is among the most hepatotoxic anabolics overall. Case reports of drug-induced liver injury (DILI), cholestasis and severe liver marker elevations are frequent in medical literature.
Pharmacokinetically orally bioavailable with about 6-8 hour half-life. Bioavailability high due to 17α-methyl group.
Known effects in studies and case reports: massive ALT/AST elevations even after 2-3 weeks, cholestasis with bilirubin rise, hypertension, strong HDL drop, joint dryness and pain, pronounced HPG suppression.
In recreational research practice Methasterone is limited to very short cycles (3-4 weeks), with active hepatoprotection stack and mandatory blood test monitoring.
Methasterone is on the WADA banned list.
You can order Methasterone as oral tablets in one bottle with 10mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Methasterone is among the most hepatotoxic anabolics overall and therefore sits at the top end of the risk scale. The effects documented in the literature are severe and can occur even after short use.
Documented in studies and the user literature:
- Severe liver strain: as a doubly methylated steroid, Methasterone is extremely hepatotoxic. Case reports of drug-induced liver injury, cholestasis and severe liver marker elevations even after 2-3 weeks are frequent in the medical literature.
- Cholestasis: cholestasis with a marked bilirubin rise is documented in case reports.
- Cardiovascular: studies describe hypertension and an unfavorable lipid profile with a strong HDL drop.
- Suppression of natural production: a pronounced HPG suppression is documented in the literature, along with joint dryness and pain.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Methasteron-Associated Cholestatic Liver Injury: Clinicopathologic Findings in 5 Cases - Clinical Gastroenterology and Hepatology 2008, Shah et al: tertiary care case series of five previously healthy patients who developed cholestatic liver injury with jaundice approximately 2 weeks after stopping methasteron use.
- Severe Hepatotoxicity Caused by a Methasteron-containing Performance-enhancing Supplement - Journal of Clinical Gastroenterology 2009, Singh et al: three case reports of severe hepatotoxicity following use of a methasteron-containing supplement, documenting progressive jaundice.
- Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol (Methasteron): A Case Report and Literature Review - Digestive Diseases and Sciences 2008, Nasr and Ahmad: case report of combined hepatic and renal injury under methasteron plus comprehensive literature review of the designer steroid.
- High amounts of 17-methylated anabolic-androgenic steroids in effervescent tablets on the dietary supplement market - Biomedical Chromatography 2007, Parr et al: analytical study quantifying methasteron and related 17-methylated designer steroids in products sold as dietary supplements.
- Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem - Andrology 2015, Rahnema et al: review article on designer steroids including methasteron with focus on hepatotoxicity, cholestasis, hypogonadism and renal failure.
